Log on / register
Feedback | Support | My details

Pre-publication history

Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial

Sandro Pignata email, Giovanni Scambia email, Antonella Savarese email, Enrico Breda email, Paolo Scollo email, Rocco De Vivo email, Emanuela Rossi email, Vittorio Gebbia email, Donato Natale email, Filomena Del Gaizo email, Emanuele Naglieri email, Antonella Ferro email, Pietro Musso email, Alfonso Maria D'Arco email, Roberto Sorio email, Carmela Pisano email, Massimo Di Maio email, Giuseppe Signoriello email, Annalisa Annunziata email and Francesco Perrone email for the MITO Investigators (see appendix)

BMC Cancer 2006, 6:202doi:10.1186/1471-2407-6-202

Pre-publication versions of this article and reviewers' reports

Original submission - Version 1Manuscript06 Apr 2006
Reviewer's ReportMaurie Markman13 Apr 2006
Reviewer's ReportRichard Penson19 Apr 2006
Resubmission - Version 2ManuscriptAuthors' comments20 May 2006
Reviewer's ReportMaurie Markman25 May 2006
Reviewer's ReportRichard Penson26 May 2006
Resubmission - Version 3ManuscriptAuthors' comments13 Jun 2006
Accepted01 Aug 2006
Terms and Conditions Privacy statement Information for advertisers Jobs at BMC Contact us
© 1999-2009 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.